dental clinics

Bio & Pharma Celltrion unveils cancer medicine to expand new drug pipelines

South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...

Korean startups Imagoworks raises $15.6 mn in Series C funding

Imagoworks, South Korea's AI-based digital dental service startup, said on Tuesday it raised 23 billion won ($15.6 million) in Series C funding.Foun...

Bio & Pharma President of Latvia visits S.Korea's Daan Cancer Lab

Daan Cancer Laboratory under Severance Hospital said on Thursday it signed a memorandum of understanding (MOU) with the Latvian government to streng...

Korean startups Mediaiplus aims to be the Amazon of clinical trials

Mediaiplus Inc., South Korea’s only provider of data analytics and contract research organization (CRO) matching services for clinical trials,...

Bio & Pharma Osstem Implant to boost digital dentistry business

South Korea's Osstem Implant Co., the world’s fourth-largest dental implant maker, will enhance its software system of digital dentistry. ...

Bio & Pharma Celltrion gets FDA nod for Keytruda copy's phase 3 clinical trials

Celltrion Inc., South Korea’s biosimilar giant, will proceed with phase 3 trials for global blockbuster drug Keytruda’s copycat CT-P51, ...

Bio & Pharma Celltrion eyes M&A in Europe, $3.3 bn Zymfentra sales: chairman

WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...

Mergers & Acquisitions Osstem to buy Brazil’s No. 3 dental implant maker Implacil

South Korea’s Osstem Implant Co., the world’s fourth-largest dental implant maker, is slated to acquire Brazilian peer Implacil De Borto...

Bio & Pharma Global quest to find modern elixirs enters new chapter

NEW YORK/ BOSTON – Longevity has long been the dream of humankind. China’s first emperor Qin Shi Huang was obsessed with finding magic e...

Tech, Media & Telecom SK Telecom to enter Australian pet clinics market in H1

South Korea’s SK Telecom Co. announced on Tuesday that it has signed a commercial contract with ATX Medical Solutions, Australia's largest m...

Bio & Pharma Aprogen gets OK Phase 3 trials in India for Herceptin biosimilar

South Korea’s biopharmaceutical company Aprogen Inc. announced on Monday that its Phase 3 clinical trial for a biosimilar of Herceptin (trastu...

Bio & Pharma LG Chem out-licenses obesity drug candidate to US firm

LG Chem Ltd. has agreed to license out a rare genetic obesity drug candidate in phase 2 clinical trials to Rhythm Pharmaceuticals Inc., a US biotech...

Bio & Pharma MedPacto gets FDA OK for colorectal cancer drug clinical trial

South Korea's biotech company MedPacto Inc. announced on Tuesday that it has got approval from the US Food and Drug Administration (FDA) for its I...

Bio & Pharma CGBio gets FDA approval for Novosis Putty

South Korea's bio-regenerative medical firm CGBio announced on Tuesday that its Novosis Putty has been designated as a breakthrough device by the US...

Upcoming IPOs Peter Thiel-backed D&D Pharmatech gets preliminary nod for IPO

South Korean clinical-stage biotech D&D Pharmatech Inc. has won approval from the Korea Exchange’s preliminary review for listing on the j...

Electronics LG Elec launches new medical monitor

LG Electronics Inc. unveiled a new medical monitor on Wednesday. This monitor boasts high brightness suitable for both clinical and diagnostic purpo...

Bio & Pharma HK inno.N reveals differentiated clinical results for K-CAB

South Korean bio-health company HK inno.N has been expanding its market by steadily announcing differentiated clinical results for its gastroesophag...

Bio & Pharma SK Bioscience applies Phase 3 trials in US for pneumococcal vaccine

South Korea's SK Bioscience Co. announced on Monday that it submitted the Investigational New Drug (IND) application for the Phase 3 clinical trial ...

Bio & Pharma Celltrion applies for approval in Europe for eye treatment biosimilar

South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it applied for approval from the European Medicines Agency (EMA) for ...

Bio & Pharma NKMax's US subsidiary listed on Nasdaq

South Korean natural killer (NK) cell drugmaker NKMax Co. on Wednesday said its US subsidiary NKGen Biotech on Monday was listed on the Nasdaq Globa...

Bio & Pharma Daewoong to develop eye drops for diabetic retinopathy

South Korea's Daewoong Pharmaceutical is venturing into the development of a product that can easily treat diabetic retinopathy in the form of ...

Bio & Pharma VaxCell Bio's treatment shows promise for advanced liver cancer

South Korea's VaxCell Biotherapeutics Co. on Tuesday said its treatment for advanced liver cancer under development stopped or greatly reduced the g...

Bio & Pharma Wellmarker Bio signs worth of $528 mn tech transfer deal

Wellmarker Bio, South Korea's oncology drug development company, announced on Monday that it has signed a technology transfer agreement with a Europ...

KOREA Investment Week Celltrion builds clinical data bank for new biosimilars

The use of data and computing is a new paradigm in the biopharmaceutical industry, reducing the new drug development time and cost, Celltrion Inc. C...

Bio & Pharma AriBio applies for Phase 3 clinical trials in China for oral dementia drug

South Korean clinical-stage biotech company AriBio Co. on Thursday said it applied for Phase 3 clinical trials on the anti-Alzheimer's candidate t...

Bio & Pharma Yungjin Pharm's new drug candidate gets Fast Track from FDA

South Korea's Yungjin Pharm has secured Fast Track designation from the US Food and Drug Administration (FDA) for its new drug candidate KL1333, des...

Bio & Pharma JW Pharma to participate in S.Korea’s new drug project

South Korea's JW Pharmaceutical announced on Monday that its experimental hair loss drug, JW0061, has been selected for a two-year funding program b...

Bio & Pharma Hanmi Pharm to start global clinical trials for immune-oncology drug

South Korea's Hanmi Pharmaceutical Co. announced on Tuesday that it has received approval for the phase 1 clinical trial plan of the immune-oncology...

Bio & Pharma JW Pharma gets OK for phase 3 clinical trials of URC102 in Taiwan

South Korea's JW Pharmaceutical has won approval from Taiwan's Food and Drug Administration (TFDA) to conduct phase 3 clinical trials for its gout t...

Bio & Pharma ABL Bio gets OK for phase 1 clinical trials for immune-oncology drug

New drug development company ABL Bio Inc. announced on Thursday that it has received approval from the Ministry of Food and Drug Safety of South Kor...